TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Gestational Diabetes Mellitus (GDM) risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sustained falls during follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Mean adherence to fall prevention recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular end‐diastolic diameter (LVEDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak oxygen uptake (VO₂)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minute ventilation/carbon dioxide production slope (VE/VCO₂)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participation in activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: communication and self-care abilities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: normal or near-normal hearing threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type A or As tympanogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection-site redness >20 mm
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate or greater drowsiness
Endpoint domain: Adverse events/effects
Primary endpoint: fewer subsequent pregnancies
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: fewer closely spaced subsequent pregnancies
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: longer intervals between the birth of the first and second child
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mean resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: rehospitalization within 90 days
Endpoint domain: Mortality/survival
Primary endpoint: cumulative number of days hospitalized during follow-up
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Average number of risk behaviors reported
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SICI of the N100 TEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SICI of the P180 TEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidences of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: sleep quantity on work/school nights
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Rate of HIV-1 acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Viral-load set point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Resistance rates to fluoroquinolones
Endpoint domain: Adverse events/effects
Primary endpoint: Emergence of resistant strains
Endpoint domain: Adverse events/effects
Primary endpoint: Fatigue severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dysentery
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of colonization with Shigella
Endpoint domain: Adverse events/effects
Primary endpoint: Volume decrease of legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anteroposterior tibial translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTX‐telopeptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: areal BMD at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: scapular muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median recovery times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from functional deficits
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Forced expiratory volume in 1 second after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in use of analgesic and nonsteroidal anti-inflammatory medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean VASP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MDQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet reactivity on clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: excellent to good outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AZ values postabsorptively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of nitrendipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of nitrendipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in oral GCS dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained oral corticosteroid cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pulmonary function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: end-expiratory H2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in 6MWT (6-Minute Walk Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in ISWT (Incremental Shuttle Walk Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour recovery of CPPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of CPPs
Endpoint domain: Mortality/survival
Primary endpoint: Change in fructosamine over 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HF-hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration response of total and all‐E lycopene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficient half‐life of all‐E and 5‐Z lycopene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cancer risk-factor determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: smoking cessation counseling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI-determined covert brain infarcts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Platelet reactivity to ADP test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities of the Arm, Shoulder and Hand score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance deficit in achieving the reversal criterion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined incidence of neurologic, neuro‐ophthalmologic, or neurobehavioral deficits or neurologic death
Endpoint domain: Mortality/survival
Primary endpoint: Geometric mean antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to Therapeutic Education System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Association between daily diabetes symptoms and nervous affect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: increase of anti-AMA-1 IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: injection site pain and swelling
Endpoint domain: Adverse events/effects
Primary endpoint: Overall colon cleanliness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: freedom from atrial arrhythmias off antiarrhythmic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change score of the 12-item Well-Being Questionnaire (WBQ-12)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants completing a WBQ-12 measure at 1 year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intention to change fat consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major and minor hemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day death or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Maternal oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level of ET-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [Na]p change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cross-sectional area of esophageal wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumferential wall tension-strain relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory thresholds for discomfort and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily dose of opiates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aqueous flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: rate of corneal endothelium loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: serum levels of IL-6, IL-1 and TNF-
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Optimal laryngeal views
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive decline measured by TICS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average overall pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean analgesic duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vasospasm-related DIDs
Endpoint domain: Mortality/survival
Primary endpoint: Duration of severe vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Platelet TXA2 receptor density (Bmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum platelet aggregation response to I‐BOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to immunosuppressive medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-item short form survey scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: kidney transplant understanding tool scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: eyestrain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection-related HIV risks
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of fear and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recognition of the identities of familiar faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Access to the names of known people
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for post-operative intervention for bleeding
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean percent body weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: IPTE occurrence
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ACUITY major bleeding hospitalization cost
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Antidepressant effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first readmission or death
Endpoint domain: Mortality/survival
Primary endpoint: Number of readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in CDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amelioration of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Mental Status Examination score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants not receiving blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximal HCV RNA reductions from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levothyroxine absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of subjects seroconverting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total signs score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days to complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global LV strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of PDI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthier and/or less bleeding teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of death
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maintaining self‐dignity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family related concerns
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: HIV‐1 RNA suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or reinfarction at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: non-inferior functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Lp(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in necessity for apheresis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: increase in sagittal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of mild ileus symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time interval to bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spontaneous bacterial peritonitis resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm delivery
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients receiving advanced life support treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal acetate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in forearm blood flow responses to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse surgical effects
Endpoint domain: Adverse events/effects
Primary endpoint: Lymphedema
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Cu concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte superoxide dismutase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: IR expression in prostate tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PaO2 decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VAS-pain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ASDAS inactive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth brushing frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintaining remission after 1 year of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV-16 antibody increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interferon-gamma response increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4 cell count stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of abutments and crowns
Endpoint domain: Mortality/survival
Primary endpoint: Biological complications
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative cystocele recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of P-ANCA and PAB positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: maximum PEG scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visible plaque percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy and nutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 90-d postdischarge hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean DAS28‐CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple organ dysfunction syndrome (MODS) recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: greater behavior change intentions
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: greater likelihood of a smoking cessation attempt
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Sensitivity of imaging for gangrenous appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of imaging for gangrenous appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of imaging for gangrenous appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of postoperative stay (LOS) for concordantly classified acute appendicitis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of postoperative stay (LOS) for concordantly classified complicated appendicitis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound infection rates in concordant and discordant 'complicated' appendicitis groups
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of mastitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median levels of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Sensitivity (MS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of continued bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Secondary metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: postoperative analgesia requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention